600062 华润双鹤
已收盘 12-31 15:00:00
资讯
新帖
简况
每周股票复盘：华润双鹤（600062）子公司获药品注册证书
证券之星 · 04:22
每周股票复盘：华润双鹤（600062）子公司获药品注册证书
华润双鹤（600062）披露设立华润双鹤产业基金完成基金备案，12月31日股价下跌0.38%
证券之星 · 12-31 18:13
华润双鹤（600062）披露设立华润双鹤产业基金完成基金备案，12月31日股价下跌0.38%
华润双鹤（600062）披露全资子公司腹膜透析液系列药品获注册证书，12月30日股价上涨0.11%
证券之星 · 12-30 17:44
华润双鹤（600062）披露全资子公司腹膜透析液系列药品获注册证书，12月30日股价上涨0.11%
华润双鹤（600062）披露2025年第三次临时股东会决议公告，12月25日股价上涨0.11%
证券之星 · 2025-12-25
华润双鹤（600062）披露2025年第三次临时股东会决议公告，12月25日股价上涨0.11%
华润双鹤：选举职工董事
证券日报 · 2025-12-25
华润双鹤：选举职工董事
华润双鹤(600062.SH)子公司DC6001片获得药物临床试验批准通知书
智通财经 · 2025-12-23
华润双鹤(600062.SH)子公司DC6001片获得药物临床试验批准通知书
华润双鹤（600062）披露拟取消监事会及变更注册资本，12月17日股价上涨1.21%
证券之星 · 2025-12-17
华润双鹤（600062）披露拟取消监事会及变更注册资本，12月17日股价上涨1.21%
华润双鹤拟取消监事会并修订多项制度，12月25日召开临时股东会审议
中金财经 · 2025-12-10
华润双鹤拟取消监事会并修订多项制度，12月25日召开临时股东会审议
华润双鹤（600062）披露全资孙公司通过GMP符合性检查，12月08日股价下跌0.27%
证券之星 · 2025-12-08
华润双鹤（600062）披露全资孙公司通过GMP符合性检查，12月08日股价下跌0.27%
华润双鹤(600062.SH)：盐酸右哌甲酯缓释胶囊纳入国家医保目录
智通财经 · 2025-12-08
华润双鹤(600062.SH)：盐酸右哌甲酯缓释胶囊纳入国家医保目录
华润双鹤(600062.SH)孙公司秦皇岛紫竹药业通过GMP符合性检查
智通财经 · 2025-12-05
华润双鹤(600062.SH)孙公司秦皇岛紫竹药业通过GMP符合性检查
华润双鹤拟回购注销部分限制性股票，注册资本将相应减少
中金财经 · 2025-12-04
华润双鹤拟回购注销部分限制性股票，注册资本将相应减少
华润双鹤修订内幕信息知情人管理制度 强化内控与合规管理
中金财经 · 2025-12-04
华润双鹤修订内幕信息知情人管理制度 强化内控与合规管理
华润双鹤拟修订董事薪酬制度，增设特别奖励机制
中金财经 · 2025-12-04
华润双鹤拟修订董事薪酬制度，增设特别奖励机制
华润双鹤(600062.SH)：盐酸吡格列酮分散片获得药品补充申请批准通知书
智通财经 · 2025-12-01
华润双鹤(600062.SH)：盐酸吡格列酮分散片获得药品补充申请批准通知书
华润双鹤（600062）34.71万股限售股将于11月28日解禁，占总股本0.03%
证券之星 · 2025-11-28
华润双鹤（600062）34.71万股限售股将于11月28日解禁，占总股本0.03%
华润双鹤(600062.SH)子公司比索洛尔氨氯地平片获得药品注册证书
智通财经 · 2025-11-25
华润双鹤(600062.SH)子公司比索洛尔氨氯地平片获得药品注册证书
华润双鹤（600062）披露2021年限制性股票激励计划预留授予部分第二个解除限售期解锁暨限制性股票上市公告，11月24日股价上涨0.54%
证券之星 · 2025-11-24
华润双鹤（600062）披露2021年限制性股票激励计划预留授予部分第二个解除限售期解锁暨限制性股票上市公告，11月24日股价上涨0.54%
每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书
证券之星 · 2025-11-23
每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书
华润双鹤(600062.SH)：奥卡西平片获得药品注册证书
智通财经 · 2025-11-18
华润双鹤(600062.SH)：奥卡西平片获得药品注册证书
加载更多
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务和输液业务三大业务。公司的主要产品是输液业务平台、慢病业务平台、专科业务平台、原料药、复方利血平氨苯蝶啶片(0号)、左炔诺孕酮片(金毓婷)、胞磷胆碱钠片(诺百益)、缬沙坦氢氯噻嗪片(复穗悦)、软袋(含直立式)。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":18.29,"timestamp":1767164400000,"preClose":18.36,"halted":0,"volume":4315744,"delay":0,"changeRate":-0.0038,"floatShares":1033000000,"shares":1039000000,"eps":1.5213,"marketStatus":"已收盘","change":-0.07,"latestTime":"12-31 15:00:00","open":18.41,"high":18.41,"low":18.25,"amount":79030800,"amplitude":0.0087,"askPrice":18.3,"askSize":456,"bidPrice":18.29,"bidSize":273,"shortable":0,"etf":0,"ttmEps":1.5213,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":18.36,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":20.2,"lowLimit":16.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038757509,"isCdr":false,"pbRate":1.68,"roa":"--","peRate":12.022612,"roe":"12.34%","epsLYR":1.5838,"committee":-0.033444,"marketValue":18999000000,"turnoverRate":0.0042,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","floatMarketCap":18893000000},"requestUrl":"/m/hq/s/600062","defaultTab":"news","newsList":[{"id":"2600039433","title":"每周股票复盘：华润双鹤（600062）子公司获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039433?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:22","pubTimestamp":1767298932,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，华润双鹤报收于18.49元，较上周的18.57元下跌0.43%。本周，华润双鹤12月22日盘中最高价报18.6元。上海长富于2023年2月启动研发，2024年8月提交上市申请并获受理，2025年12月获批。截至目前累计研发投入2,044.57万元。华润双鹤收到国家药监局签发的羟钴胺注射液《药物临床试验批准通知书》，同意开展用于儿童甲基丙二酸血症伴或不伴同型半胱氨酸血症患者代谢紊乱的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600062","BK0010","BK0175","BK0028","BK0185"],"gpt_icon":0},{"id":"2595778265","title":"华润双鹤（600062）披露设立华润双鹤产业基金完成基金备案，12月31日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778265?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:13","pubTimestamp":1767176016,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，华润双鹤报收于18.29元，较前一交易日下跌0.38%，最新总市值为189.99亿元。公司近日发布公告称，华润双鹤药业股份有限公司认缴出资8,300万元参与设立华润双鹤生物医药产业基金投资合伙企业，基金目标募集规模为5亿元。该基金已完成在中国证券投资基金业协会的备案，备案编码为SBML96，管理人为深圳市华润资本股权投资有限公司，托管人为中国工商银行股份有限公司，备案日期为2025年12月29日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100034027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0188","600062","BK0010","BK0239","BK0175"],"gpt_icon":0},{"id":"2595793001","title":"华润双鹤（600062）披露全资子公司腹膜透析液系列药品获注册证书，12月30日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595793001","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595793001?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:44","pubTimestamp":1767087894,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，华润双鹤报收于18.36元，较前一交易日上涨0.11%，最新总市值为190.72亿元。该股当日开盘18.31元，最高18.39元，最低18.24元，成交额达6561.9万元，换手率为0.35%。公司近日发布公告称，其全资子公司上海长征富民金山制药有限公司获得国家药监局颁发的低钙腹膜透析液和腹膜透析液系列药品的《药品注册证书》，规格均为2000ml，注册分类为化学药品3类，视同通过一致性评价。截至目前累计研发投入2,044.57万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0028","BK0175","BK0010","BK0188","BK0185","BK0239"],"gpt_icon":0},{"id":"2594923721","title":"华润双鹤（600062）披露2025年第三次临时股东会决议公告，12月25日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594923721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594923721?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:41","pubTimestamp":1766673680,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，华润双鹤报收于18.48元，较前一交易日上涨0.11%，最新总市值为191.96亿元。该股当日开盘18.47元，最高18.52元，最低18.4元，成交额达6615.03万元，换手率为0.35%。公司近日发布公告称，华润双鹤药业股份有限公司于2025年12月25日召开2025年第三次临时股东会，审议通过了关于变更注册资本、修订公司章程、取消监事会、全面修订公司基本管理制度等相关议案。会议由董事赵骞主持，出席会议的股东所持有表决权股份数占公司总股本的61.5324%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","600062","BK0239","BK0175","BK0188","BK0010"],"gpt_icon":0},{"id":"2594234384","title":"华润双鹤：选举职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594234384","media":"证券日报 ","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594234384?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:08","pubTimestamp":1766664480,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月25日，华润双鹤发布公告称，公司于近日召开职工代表大会，经职工代表民主选举，一致同意选举姚东晗女士为公司第十届董事会职工董事。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-25/doc-inhcznyc3209826.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-25/doc-inhcznyc3209826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0185","BK0028","BK0239","BK0010","BK0175","600062"],"gpt_icon":0},{"id":"2593935494","title":"华润双鹤(600062.SH)子公司DC6001片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593935494","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593935494?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:57","pubTimestamp":1766480254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司北京双鹤润创科技有限公司(简称“双鹤润创”)收到了国家药品监督管理局颁发的DC6001片《药物临床试验批准通知书》。DC6001片拟用于青少年遗传性黄斑变性疾病(Stargardt病)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司DC6001片获得药物临床试验批准通知书","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0028","BK0188","BK0010","600062","BK0185","BK0239"],"gpt_icon":0},{"id":"2592915850","title":"华润双鹤（600062）披露拟取消监事会及变更注册资本，12月17日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915850?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:11","pubTimestamp":1765980695,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，华润双鹤报收于18.42元，较前一交易日上涨1.21%，最新总市值为191.34亿元。近日，华润双鹤发布关于召开2025年第三次临时股东会的会议文件。公告显示，公司将审议变更注册资本、修订公司章程、取消监事会及全面修订公司基本管理制度等议案。因回购注销17.4998万股限制性股票，注册资本将由103,875.7509万元减至103,858.2511万元。公司监事会拟被取消，其原有职能将由董事会审计与风险管理委员会承担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0010","600062","BK0175","BK0188","BK0239"],"gpt_icon":0},{"id":"2590953305","title":"华润双鹤拟取消监事会并修订多项制度，12月25日召开临时股东会审议","url":"https://stock-news.laohu8.com/highlight/detail?id=2590953305","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590953305?lang=zh_cn&edition=full","pubTime":"2025-12-10 14:25","pubTimestamp":1765347923,"startTime":"0","endTime":"0","summary":"中访网数据 华润双鹤药业股份有限公司将于2025年12月25日召开2025年第三次临时股东会，审议多项重要议案。核心内容包括拟取消公司监事会，并全面修订公司基本管理制度，涉及《股东会议事规则》《董事会议事规则》《独立董事工作细则》等多项核心治理文件。同时，会议还将审议因公司股份回购注销而需进行的注册资本变更及相应《公司章程》修订。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31855948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","BK0188","BK0185","BK0239","600062","BK0175","BK0010"],"gpt_icon":0},{"id":"2589339866","title":"华润双鹤（600062）披露全资孙公司通过GMP符合性检查，12月08日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339866?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:48","pubTimestamp":1765187298,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，华润双鹤报收于18.74元，较前一交易日下跌0.27%，最新总市值为194.66亿元。公司近日发布公告称，其全资孙公司秦皇岛紫竹药业有限公司收到河北省药品监督管理局颁发的雌三醇原料药《药品GMP符合性检查告知书》。本次检查为雌三醇原料药上市前的首次GMP符合性检查，未投入资金。目前国家药监局原辅包登记平台显示共有2家企业登记雌三醇原料药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800022067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0175","BK0028","BK0010","BK0185","600062"],"gpt_icon":0},{"id":"2589133657","title":"华润双鹤(600062.SH)：盐酸右哌甲酯缓释胶囊纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589133657","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589133657?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:31","pubTimestamp":1765186315,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，公司控股公司河南中帅药业有限公司(控股子公司河南中帅医药科技有限责任公司之全资子公司)的产品盐酸右哌甲酯缓释胶囊通过医保谈判纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称“《国家医保目录》”)，协议期内谈判药品按照乙类支付。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：盐酸右哌甲酯缓释胶囊纳入国家医保目录","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0185","BK0028","600062","BK0188","BK0010","BK0175"],"gpt_icon":0},{"id":"2589898315","title":"华润双鹤(600062.SH)孙公司秦皇岛紫竹药业通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2589898315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589898315?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:10","pubTimestamp":1764925842,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资孙公司秦皇岛紫竹药业有限公司(简称“秦皇岛紫竹”)收到河北省药品监督管理局颁发的雌三醇原料药《药品GMP符合性检查告知书》[编号：冀药监化药符(2025)151号]。检查范围及相关车间、生产线：原料药(雌三醇，多功能车间生产线10)。公司本次通过药品GMP符合性检查，表明公司产品生产质量管理符合GMP要求，将有利于公司继续保持稳定的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK0028","BK0010","BK0185","600062","BK0175"],"gpt_icon":0},{"id":"2588077050","title":"华润双鹤拟回购注销部分限制性股票，注册资本将相应减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2588077050","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588077050?lang=zh_cn&edition=full","pubTime":"2025-12-04 12:24","pubTimestamp":1764822269,"startTime":"0","endTime":"0","summary":"中访网数据 华润双鹤药业股份有限公司于2025年12月2日召开第十届董事会第十五次会议，审议通过了关于变更公司注册资本的议案。此次回购注销完成后，公司的股份总数将由原103,875.7509万股变更为103,858.2511万股，公司的注册资本也将相应由103,875.7509万元减少至103,858.2511万元。根据公告，此项变更注册资本事宜尚需提交公司股东大会审议批准后方可实施。此次变动反映了公司对股权激励计划的规范管理，并将对公司股权结构和注册资本产生直接影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31843877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0185","BK0010","BK0188","BK0028","BK0239","BK0175","600062"],"gpt_icon":0},{"id":"2588741072","title":"华润双鹤修订内幕信息知情人管理制度 强化内控与合规管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588741072","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588741072?lang=zh_cn&edition=full","pubTime":"2025-12-04 11:32","pubTimestamp":1764819129,"startTime":"0","endTime":"0","summary":"中访网数据 华润双鹤药业股份有限公司于近日修订并通过了《内幕信息知情人管理制度》，旨在进一步规范公司内幕信息管理，加强保密工作，以维护信息披露的公平原则。制度规定，内幕信息知情人档案和重大事项进程备忘录需至少保存十年，并需及时向上海证券交易所报送。此次制度修订体现了华润双鹤持续完善公司治理、强化内部控制和合规管理体系的决心，以防范内幕交易风险，保护投资者合法权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31843766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0185","BK0028","BK0239","BK0010","BK0175","600062"],"gpt_icon":0},{"id":"2588729170","title":"华润双鹤拟修订董事薪酬制度，增设特别奖励机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2588729170","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588729170?lang=zh_cn&edition=full","pubTime":"2025-12-04 11:26","pubTimestamp":1764818767,"startTime":"0","endTime":"0","summary":"中访网数据 华润双鹤药业股份有限公司于近期披露了经董事会修订的《董事薪酬制度》。核心修订内容为增设董事特别奖励机制。根据新制度，经董事长提议、董事会审议通过，可对本年度在履职过程中作出突出贡献的董事发放特别奖励，该奖励议案需报公司年度股东大会批准后执行。此项特别奖励的发放，不受原有制度中关于“在控参股公司担任其他职务并领薪的董事不再领取董事薪酬”这一原则的限制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31843744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0239","BK0010","600062","BK0185","BK0028","BK0175"],"gpt_icon":0},{"id":"2588723866","title":"华润双鹤(600062.SH)：盐酸吡格列酮分散片获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2588723866","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588723866?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:20","pubTimestamp":1764580822,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司控股子公司双鹤天安药业(贵州)股份有限公司(简称“双鹤天安”)收到了国家药品监督管理局颁发的盐酸吡格列酮分散片《药品补充申请批准通知书》。经审查，该药品视同通过仿制药质量和疗效一致性评价。盐酸吡格列酮分散片用于2型糖尿病的治疗。本次盐酸吡格列酮分散片通过一致性评价将有利于未来的市场销售和市场竞争，并为后续开展仿制药一致性评价积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：盐酸吡格列酮分散片获得药品补充申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0010","600062","BK0185","BK0028","BK0175"],"gpt_icon":0},{"id":"2586275122","title":"华润双鹤（600062）34.71万股限售股将于11月28日解禁，占总股本0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586275122","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586275122?lang=zh_cn&edition=full","pubTime":"2025-11-28 08:06","pubTimestamp":1764288365,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，华润双鹤于11月28日将有34.71万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.03%。最近一年内，该股累计解禁577.78万股，占总股本的0.56%。本次解禁后，公司还有577.96万股限售股份，占总股本0.56%。华润双鹤主营业务：慢病业务、专科业务和输液业务三大业务平台。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800003305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0010","BK0188","BK0028","BK0239","BK0175","600062"],"gpt_icon":0},{"id":"2586423308","title":"华润双鹤(600062.SH)子公司比索洛尔氨氯地平片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586423308","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586423308?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:54","pubTimestamp":1764060853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司华润赛科药业有限责任公司(简称“华润赛科”)收到了国家药品监督管理局颁发的比索洛尔氨氯地平片《药品注册证书》。比索洛尔氨氯地平片作为高血压治疗的替代疗法，用于目前同时服用与复方制剂剂量相同的单药且血压控制良好的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062","BK0028","BK0175","BK0010","EWW","BK0188","MXPmain","BK0185","BK0239"],"gpt_icon":0},{"id":"2585146046","title":"华润双鹤（600062）披露2021年限制性股票激励计划预留授予部分第二个解除限售期解锁暨限制性股票上市公告，11月24日股价上涨0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585146046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585146046?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:13","pubTimestamp":1763993619,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，华润双鹤报收于18.61元，较前一交易日上涨0.54%，最新总市值为193.31亿元。该股当日开盘18.55元，最高18.71元，最低18.5元，成交额达1亿元，换手率为0.52%。公司近日发布公告，披露关于2021年限制性股票激励计划预留授予部分第二个解除限售期解锁暨限制性股票上市的相关情况。公告显示，本次解除限售的激励对象为40人，解除限售股票数量为347,068股，占公司总股本的0.03%。本次解锁股票上市流通日期为2025年11月28日，上市流通数量为347,068股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600062","BK0239","BK0028","BK0010","BK0185","BK0175"],"gpt_icon":0},{"id":"2585108065","title":"每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108065","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108065?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:57","pubTimestamp":1763834228,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，华润双鹤报收于18.51元，较上周的19.57元下跌5.42%。本周，华润双鹤11月17日盘中最高价报19.55元。本周关注点公司公告汇总：控股子公司奥卡西平片获药品注册证书，视同通过一致性评价。公司公告汇总华润双鹤控股子公司湖南省湘中制药有限公司近日获得国家药监局颁发的奥卡西平片《药品注册证书》，规格为0.3g，注册分类为化学药品4类，视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0010","600062","BK0175","BK0188","BK0239"],"gpt_icon":0},{"id":"2584998053","title":"华润双鹤(600062.SH)：奥卡西平片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2584998053","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584998053?lang=zh_cn&edition=full","pubTime":"2025-11-18 17:02","pubTimestamp":1763456572,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司控股子公司湖南省湘中制药有限公司(以下简称“湘中制药”)收到了国家药品监督管理局(以下简称“国家药监局”)颁发的奥卡西平片(以下简称“该药品”)《药品注册证书》。奥卡西平片用于治疗成年人和5岁及以上儿童的原发性全面性强直-阵挛发作和部分性发作，伴有或不伴有继发性全面性发作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：奥卡西平片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062","BK0239","BK0175","BK0188","BK0010","BK0185","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767325098305,"stockEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":-0.0282},{"period":"3month","weight":-0.0158},{"period":"6month","weight":-0.0083},{"period":"1year","weight":-0.0529},{"period":"ytd","weight":-0.0529}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"57726人(较上一季度增加0.51%)","perCapita":"17894股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103875万元","survey":" 华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务和输液业务三大业务。公司的主要产品是输液业务平台、慢病业务平台、专科业务平台、原料药、复方利血平氨苯蝶啶片(0号)、左炔诺孕酮片(金毓婷)、胞磷胆碱钠片(诺百益)、缬沙坦氢氯噻嗪片(复穗悦)、软袋(含直立式)。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}